Skip to main content
Venus Remedies Ltd. logo

Venus Remedies Ltd. — Investor Relations & Filings

Ticker · VENUSREM ISIN · INE411B01019 LEI · 335800PBHMB6GQMFN127 BSE.NS Manufacturing
Open in API
Filings indexed 620 across all filing types
Latest filing 2026-05-28 Earnings Release
Country IN India
Listing BSE.NS VENUSREM

About Venus Remedies Ltd.

https://venusremedies.com/

Venus Remedies Ltd. is a research-driven organization specializing in the development and manufacturing of innovative pharmaceutical formulations. The company focuses on critical therapeutic segments, including antimicrobial resistance, oncology, neurology, orthopedics, and pain management. It operates advanced manufacturing facilities and maintains a dedicated research and development wing, the Venus Medicine Research Centre, which prioritizes the creation of novel drug delivery systems and solutions for multi-drug resistant infections. Its product portfolio features a diverse range of injectables and specialized treatments, such as Elores, aimed at addressing complex clinical needs. The company serves a global market, providing healthcare solutions through a commitment to scientific excellence and international regulatory standards.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Earnings Release Classification · 62% confidence The document is a newspaper publication under SEBI LODR Regulation 30, providing audited financial results for quarter and year ended 31.03.2026. It is not the full annual report but the initial public announcement of periodical financial results (with summary numbers). This matches the description of an Earnings Release (ER), which covers key financial highlights for a reporting period. FY 2026
2026-05-28 English
As per enclosed file.
Regulatory Filings Classification · 75% confidence The document is an exchange filing under Regulation 30 of the LODR, specifically a newspaper publication of ‘Extracts of Audited Financial Results’ for the period ended 31.03.2026. It is not the full annual report or standalone audit report but a compliance announcement to the stock exchanges with summary financial data published in a newspaper. This makes it a general regulatory announcement rather than a formal 10-K, IR, ER or other specific reporting form. Therefore it falls under the Regulatory Filings (RNS) category.
2026-05-28 English
Updates
Regulatory Filings Classification · 87% confidence The document is the formal stock‐exchange filing under Regulation 30/33 of the SEBI LODR as an “Outcome of Board Meeting.” It discloses audited financial results (with audit report annexed), AGM scheduling, dividend record date, director and auditor appointments, MOA/AOA adoption and related compliance items. It is not itself a full Annual or Interim report, nor purely an earnings press release or management discussion. This type of general regulatory bulletin is best mapped to the “Regulatory Filings” fallback category (RNS).
2026-05-26 English
Updates
Regulatory Filings Classification · 85% confidence The document is an exchange filing disclosing the outcome of a Board meeting under SEBI Listing Regulations (Reg 30 & 33). It summarizes approval of audited quarterly and annual financial results (with annexed audit report), AGM date, dividend record date, director and auditor appointments, and amendments to MOA/AOA. It is not the full Annual Report or the standalone financial statements themselves, but a regulatory announcement of board decisions and attached results. This falls under general regulatory disclosures. Therefore, it is classified as Regulatory Filings.
2026-05-26 English
Appointment
Regulatory Filings Classification · 80% confidence The document is a stock‐exchange regulatory disclosure under SEBI LODR (Reg. 30 & 33) titled “Outcome of Board Meeting,” reporting audited financial results, AGM scheduling, dividend record date, director and auditor appointments, adoption of MOA/AOA, and trading window closure. It does not contain the full annual report narrative, detailed management discussion, or pure audit findings alone. It is not a simple earnings release (which would just summarise key highlights), nor a full interim or annual report, but a general exchange filing disclosing multiple corporate actions. Therefore, it is a miscellaneous regulatory announcement best classified as Regulatory Filings (RNS).
2026-05-26 English
Appointment
Regulatory Filings Classification · 87% confidence The document is headed as an ‘Outcome of Board Meeting’ sent to stock exchanges (NSE/BSE) under SEBI LODR regulation 30. It summarizes board approvals: audited financial results (with audit report annexed), AGM date, dividend record date, director appointments/reappointments, auditor appointments, MOA/AOA adoption, and trading window closure. It is not the full annual or interim report itself but a regulatory announcement. This falls under the catch-all Regulatory Filings category (RNS), not a standalone report or a change-of-management notice only.
2026-05-26 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.